BRPI0918045A2 - compostos de carboxamida heterocíclicos - Google Patents

compostos de carboxamida heterocíclicos

Info

Publication number
BRPI0918045A2
BRPI0918045A2 BRPI0918045A BRPI0918045A BRPI0918045A2 BR PI0918045 A2 BRPI0918045 A2 BR PI0918045A2 BR PI0918045 A BRPI0918045 A BR PI0918045A BR PI0918045 A BRPI0918045 A BR PI0918045A BR PI0918045 A2 BRPI0918045 A2 BR PI0918045A2
Authority
BR
Brazil
Prior art keywords
carboxamide compounds
heterocyclic carboxamide
heterocyclic
compounds
carboxamide
Prior art date
Application number
BRPI0918045A
Other languages
English (en)
Inventor
Hideyuki Watanabe
Jun Maeda
Noe Ishii
Satoshi Kubo
Shinji Itoh
Shinji Shigenaga
Takeshi Terasawa
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of BRPI0918045A2 publication Critical patent/BRPI0918045A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BRPI0918045A 2008-09-18 2009-09-17 compostos de carboxamida heterocíclicos BRPI0918045A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9797908P 2008-09-18 2008-09-18
PCT/JP2009/066840 WO2010032875A2 (en) 2008-09-18 2009-09-17 Heterocyclic carboxamide compounds

Publications (1)

Publication Number Publication Date
BRPI0918045A2 true BRPI0918045A2 (pt) 2015-12-01

Family

ID=41682377

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918045A BRPI0918045A2 (pt) 2008-09-18 2009-09-17 compostos de carboxamida heterocíclicos

Country Status (9)

Country Link
US (1) US20110166161A1 (pt)
EP (1) EP2331507A2 (pt)
JP (1) JP2012502882A (pt)
KR (1) KR20110060894A (pt)
CN (1) CN102159547A (pt)
BR (1) BRPI0918045A2 (pt)
CA (1) CA2737738A1 (pt)
MX (1) MX2011002825A (pt)
WO (1) WO2010032875A2 (pt)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8138339B2 (en) 2008-04-16 2012-03-20 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
US8063058B2 (en) 2008-04-16 2011-11-22 Portola Pharmaceuticals, Inc. Inhibitors of syk and JAK protein kinases
US8748623B2 (en) 2009-02-17 2014-06-10 Syntrix Biosystems, Inc. Pyridinecarboxamides as CXCR2 modulators
GB201018996D0 (en) * 2010-11-10 2010-12-22 Amakem Nv Novel ROCK inhibitors
EP2608672B1 (en) * 2010-08-23 2020-12-16 Syntrix Biosystems, Inc. Aminopyridine- and aminopyrimidinecarboxamides as cxcr2 modulators
US9139534B2 (en) 2011-04-22 2015-09-22 Signal Pharmaceuticals, Llc Substituted diaminocarboxamide and diaminocarbonitrile pyrimidines, compositions thereof, and methods of treatment therewith
MX363551B (es) 2011-11-23 2019-03-27 Portola Pharmaceuticals Inc Star Compuestos derivados de pirazina como inhibidores de cinasa.
US8969365B2 (en) 2013-08-02 2015-03-03 Syntrix Biosystems, Inc. Thiopyrimidinecarboxamides as CXCR1/2 modulators
US10046002B2 (en) 2013-08-02 2018-08-14 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
US10561676B2 (en) 2013-08-02 2020-02-18 Syntrix Biosystems Inc. Method for treating cancer using dual antagonists of CXCR1 and CXCR2
NZ715903A (en) 2014-01-30 2017-06-30 Signal Pharm Llc Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
CN107108524A (zh) 2014-12-16 2017-08-29 西格诺药品有限公司 2‑(叔丁基氨基)‑4‑((1r,3r,4r)‑3‑羟基‑4‑甲基环己基氨基)‑嘧啶‑5‑甲酰胺的配制物
US9513297B2 (en) 2014-12-16 2016-12-06 Signal Pharmaceuticals, Llc Methods for measurement of inhibition of c-Jun N-terminal kinase in skin
EP3250557B1 (en) 2015-01-29 2024-11-20 Signal Pharmaceuticals, LLC Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
CN107922287B (zh) 2015-07-24 2021-04-09 细胞基因公司 合成(1r,2r,5r)-5-氨基-2-甲基环己醇盐酸盐的方法和其中可用的中间体
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
TWI800498B (zh) 2016-12-21 2023-05-01 義大利商吉斯藥品公司 作為Rho-激酶抑制劑之雙環二氫嘧啶-羧醯胺衍生物
GEP20207202B (en) 2017-01-30 2020-12-25 Chiesi Farm Spa Tyrosine amide derivatives as rho-kinase inhibitors
EP3652165B1 (en) * 2017-07-12 2021-08-25 Bristol-Myers Squibb Company Five membered-aminoheterocyclic and 5,6-or 6,6-membered bicyclic aminoheterocyclic inhibitors of rock for the treatment of heart failure
CN110869360B (zh) * 2017-07-12 2023-12-15 百时美施贵宝公司 作为rock抑制剂的苯乙酰胺类
TW201908293A (zh) 2017-07-12 2019-03-01 美商必治妥美雅史谷比公司 作為rock抑制劑之5員及雙環雜環醯胺
WO2019048479A1 (en) 2017-09-07 2019-03-14 Chiesi Farmaceutici S.P.A. DERIVATIVES OF TYROSINE ANALOGS AS INHIBITORS OF RHO-KINASE
US11332468B2 (en) 2017-12-18 2022-05-17 Chiesi Farmaceutici S.P.A. Azaindole derivatives as Rho-kinase inhibitors
MA51283A (fr) 2017-12-18 2021-05-26 Chiesi Farm Spa Dérivés de tyrosine en tant qu'inhibiteurs de kinase rho
EP3728247B1 (en) 2017-12-18 2021-09-22 Chiesi Farmaceutici S.p.A. Oxadiazole derivatives as rho-kinase inhibitors
CN108218829A (zh) * 2017-12-31 2018-06-29 佛山市赛维斯医药科技有限公司 一种噻吩酰胺类rock抑制剂、制备方法及其用途
CN108047197A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 硝基噻吩酰胺rock抑制剂、制备方法及其用途
CN108558823A (zh) * 2017-12-31 2018-09-21 佛山市赛维斯医药科技有限公司 一类腈基噻吩酰胺rock抑制剂、制备方法及其用途
CN108047195A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 一种含丙二醇腈基噻吩酰胺类化合物及其用途
CN108129452A (zh) * 2017-12-31 2018-06-08 佛山市赛维斯医药科技有限公司 一种含异丙基萘和丙二醇硝基噻吩酰胺类化合物及其用途
CN108101885A (zh) * 2017-12-31 2018-06-01 佛山市赛维斯医药科技有限公司 含异丙胺和硝基噻吩酰胺类结构化合物、其制备方法及用途
CN107973777A (zh) * 2017-12-31 2018-05-01 佛山市赛维斯医药科技有限公司 一种含甲基萘和丙二醇噻吩酰胺类rock抑制剂及其用途
CN107973776A (zh) * 2017-12-31 2018-05-01 佛山市赛维斯医药科技有限公司 一种噻吩酰胺类结构化合物及其用途
CN108191820A (zh) * 2017-12-31 2018-06-22 佛山市赛维斯医药科技有限公司 一种含异丙胺和噻吩酰胺类结构的化合物
CN108047193A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 烷氧噻吩酰胺类rock抑制剂、制备方法及其用途
CN107935987A (zh) * 2017-12-31 2018-04-20 佛山市赛维斯医药科技有限公司 含甲基萘和噻吩酰胺结构的rock抑制剂、制备方法及其用途
CN107935986A (zh) * 2017-12-31 2018-04-20 佛山市赛维斯医药科技有限公司 异丙胺和卤代噻吩酰胺类结构化合物、其制备方法及用途
CN108129453A (zh) * 2017-12-31 2018-06-08 佛山市赛维斯医药科技有限公司 一种含甲基萘和丙二醇噻吩酰胺类结构的rock抑制剂
CN107915717A (zh) * 2017-12-31 2018-04-17 佛山市赛维斯医药科技有限公司 一类含异丙基萘和丙二醇噻吩酰胺类化合物及其用途
CN108047194A (zh) * 2017-12-31 2018-05-18 佛山市赛维斯医药科技有限公司 含甲基萘和丙二醇噻吩酰胺类化合物、制备方法及其用途
AR114926A1 (es) 2018-06-13 2020-10-28 Chiesi Farm Spa Derivados de azaindol como inhibidores de rho-quinasa
TW202019923A (zh) 2018-07-16 2020-06-01 義大利商吉斯藥品公司 作為Rho-激酶抑制劑之酪胺酸醯胺衍生物
EP4263546B1 (en) 2020-12-15 2025-07-02 Chiesi Farmaceutici S.p.A. Dihydrofuropyridine derivatives as rho- kinase inhibitors
MX2023005866A (es) 2020-12-15 2023-06-05 Chiesi Farm Spa Derivados de dihidrofuropiridina como inhibidores de rho-cinasa.
CA3202146A1 (en) 2020-12-15 2022-06-23 Fabio Rancati Dihydrofuropyridine derivatives as rho- kinase inhibitors
WO2023110700A1 (en) 2021-12-13 2023-06-22 Chiesi Farmaceutici S.P.A. Dihydrofuropyridine derivatives as rho-kinase inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9711154A (pt) * 1996-08-12 1999-08-17 Yoshitomi Pharmaceutical Agente farmac-utico contendo inibidor cinase rho
CA2307285C (en) * 1998-08-17 2009-03-31 Senju Pharmaceutical Co., Ltd. Agent for prophylaxis and treatment of glaucoma
TWI243162B (en) * 2000-11-10 2005-11-11 Taisho Pharmaceutical Co Ltd Cyanopyrrolidine derivatives
CA2433090A1 (en) * 2000-12-27 2002-07-04 Kyowa Hakko Kogyo Co., Ltd. Dipeptidyl peptidase iv inhibitor
AU2003220935A1 (en) * 2002-04-03 2003-10-13 Sumitomo Pharmaceuticals Company, Limited. Benzamide derivatives
US7094789B2 (en) * 2002-07-22 2006-08-22 Asahi Kasei Pharma Corporation 5-substituted isoquinoline derivatives
AU2003264427A1 (en) * 2002-09-12 2004-04-30 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
TWI335913B (en) * 2002-11-15 2011-01-11 Vertex Pharma Diaminotriazoles useful as inhibitors of protein kinases
US7160894B2 (en) * 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
EP1679308B1 (en) * 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
BRPI0417156A (pt) * 2003-12-12 2007-03-06 Lilly Co Eli composto, composição farmacêutica, e, métodos para bloquear receptor mu, capa, delta ou combinação (heterodìmero) dos mesmos em mamìferos, para tratar e/ou prevenir doenças relacionadas com obesidade e obesidade, para suprimir apetite em um paciente, para efetuar perda de peso em um paciente obeso
ES2364340T3 (es) * 2004-03-30 2011-08-31 Vertex Pharmaceuticals Incorporated Azaindoles útiles como inhibidores de jak y otras proteína quinasas.
WO2006135383A2 (en) * 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
WO2008019967A2 (en) * 2006-08-15 2008-02-21 F. Hoffmann-La Roche Ag Phenyl, pyridine and quinoline derivatives

Also Published As

Publication number Publication date
CA2737738A1 (en) 2010-03-25
MX2011002825A (es) 2011-04-05
KR20110060894A (ko) 2011-06-08
WO2010032875A2 (en) 2010-03-25
US20110166161A1 (en) 2011-07-07
CN102159547A (zh) 2011-08-17
EP2331507A2 (en) 2011-06-15
WO2010032875A3 (en) 2010-06-10
JP2012502882A (ja) 2012-02-02

Similar Documents

Publication Publication Date Title
BRPI0918045A2 (pt) compostos de carboxamida heterocíclicos
CY2020004I1 (el) Eνωση διαμινο ετεροκυκλικου καρβοξαμιδιου
BRPI0906705A2 (pt) Composto heterocíclicos
BRPI0916233A2 (pt) compostos heterocíclicos antivirais
EP2376493A4 (en) DIHYDROPYRIMIDOPYRIMIDINDERIVAT
EP2380877A4 (en) PYRIDINE-3-CARBONSÄUREAMIDDERIVAT
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
EP2298731A4 (en) AMIDE COMPOUND
DK2308877T3 (da) Imidazopyridin-2-on-derivater
DK2242759T3 (da) Forbindelser
EP2251326A4 (en) HETEROCYCLIC COMPOUND
DK2340021T3 (da) Substituerede pyrrolidin-2-carboxamider
EP2266989A4 (en) HETEROCYCLIC DERIVATIVES
BRPI0915064A2 (pt) derivados de qunoxalinadiona
BR112012008061A2 (pt) compostos de oxima heterocíclica
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
EP2336132A4 (en) MORPHOLINPURINDERIVAT
DK2323972T3 (da) C7-fluor-substituerede tetracylinforbindelser
DK2275414T3 (da) Cyclopentylacrylamidderivat
DK2297162T3 (da) Forbindelser
BRPI0924121A2 (pt) compostos antivirais heterocíclicos
BRPI0906357A2 (pt) Derivados de oxazepinopirimidona arilamida substituídos
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
HRP20150932T1 (xx) Heterocikliäśki spojevi

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 4A, 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2385 DE 20-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.